Objectives We aim to develop non-invasive prenatal diagnosis (NIPD) for cystic fibrosis (CF) and determine costs and implications for implementation.
INTRODUCTION
Cystic fibrosis (CF) is a severe, autosomal recessive, multisystem condition, predominantly affecting the respiratory and digestive systems. CF is caused by mutations, of which there are more than 1900, in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The prevalence of CF is 1 in 2500 to 1 in 3500 live births, and for people with Northern European ancestry, the carrier frequency is 1 in 25.
1 Advances in multi-disciplinary care have improved long-term outcomes for people with CF. In the UK, median survival is now 43 years. 2, 3 Prenatal diagnosis of CF currently requires an invasive test to obtain fetal genetic material and so carries a small risk of miscarriage 4 but is an option that is valued by carrier couples as it allows them to either plan and prepare for the birth of an affected child or make decisions about termination of pregnancy. 5 Non-invasive prenatal diagnosis (NIPD) based on analysis of cell-free fetal DNA (cffDNA) in maternal plasma has been reported to exclude the paternal mutation in couples carrying different CF mutations. [6] [7] [8] However, these reports described analyses developed for individual families, a labour-intensive approach for implementation into routine clinical practice. Here, we describe the development of a next-generation sequencing (NGS) assay designed to detect or exclude ten of the most common CF mutations, for use when each parent carries a different CFTR mutation and the paternal mutation is one of the ten included in this panel. To inform implementation strategies, we also report a cost analysis of NIPD for CF, which was informed by an exploration of stakeholder preferences through a questionnaire-based survey of potential service users and providers.
METHODS

Ethical approval
National Health Service Research Ethics Committee approval was obtained for the collection of maternal and paternal blood samples for NIPD test development (01/0095) and for the questionnaire study (10/H0714/3).
Development of the NIPD assay Sample collection
Normal and heterozygous genomic DNA (gDNA) control samples with known CFTR mutations were ascertained from our Regional Genetics Laboratory records and used to assess test performance, before testing on maternal plasma samples collected, as part of a larger programme designed to develop standards for NIPD (RAPID RP-PG-0707-10107), from women undergoing invasive diagnostic prenatal testing because of a risk of CF. Outcome of invasive testing was known in all cases.
Sample processing and DNA extraction
Maternal plasma samples were separated from 20 mL of blood within 48 h of blood draw and processed for storage at À80°C as previously described. 10 The cell free DNA (cfDNA) was extracted from 4 mL of maternal plasma using the QIAsymphony into a final volume of 60 μL EB buffer (Qiagen). The gDNA was extracted from 2 mL of blood with the Quickgene-610L Nucleic Acid Isolation System (Fujifilm) into a final volume of 200 μL elution buffer.
Next-generation DNA sequencing
Ten CFTR mutations commonly seen in our regional genetics service, including those on the UK neonatal screening panel, were selected. A targeted amplicon approach was used. PCR primers were designed, using Primer 3 software, to amplify five amplicons of CFTR covering these ten mutations (Table 1) and the ZFX/ZFY and HLA-B genes. Each amplicon was individually optimised. Mutation targets for each patient DNA sample were given a common molecular barcode and were amplified in individual single-plex PCRs. PCR was carried out using 10 μL of Phusion High-Fidelity PCR Master Mix (NEB), 500 nM of each primer in a final reaction volume of 20 μL. Cycling conditions were 98°C for 1 min, followed by 42 cycles of 98°C for 10 s, 64°C for 30 s and 72°C for 30 s, followed by 72°C for 10 min. Amplicons were pooled and purified using a MinElute PCR Purification Kit (Qiagen), quantified using a Qubit dsDNA BR Assay Kit (Invitrogen) and amplicon quality assessed using a Bioanalyzer (Agilent). Purified PCR products were diluted to 2 nM in Elution Buffer (Qiagen), and samples were pooled to give a single 2 nM library. This pooled library was denatured using 2 M sodium hydroxide, diluted to 8 pM and mixed with an 8 pM PhiX control to give a 20% PhiX spike, providing sequence diversity. The library was sequenced with the Illumina MiSeq using a single-end 100-cycle protocol. After de-multiplexing, the number of reads containing the wild-type and mutant alleles was counted for each target site. The presence of fetal DNA was confirmed by the detection of paternal CFTR sequences, ZFY or paternal HLA-type sequences in the maternal plasma.
Estimation of assay applicability
The ten mutations included in the NGS assay have a combined allele frequency of 77%. 11 We estimated how many couples would be eligible to use this assay using the reported allele frequency 11 for each mutation on the panel to determine the probability that the father has the mutation and the mother does not have the mutation (Table 2) .
Health economics
To assess the economic consequences of implementing NIPD for prenatal diagnosis of CF, we estimated the total test-related costs of three different clinical pathways: the current invasive testing only pathway, NIPD for the paternal CF mutation and NIPD for direct diagnosis ( Figure 1) . A questionnaire-based study of stakeholder views and preferences was undertaken to estimate the uptake of invasive testing and NIPD with detailed results published elsewhere. 9 In brief, adult patients with CF and carriers of CF attending one children's and one adult NHS regional specialist CF centre serving large geographical areas were invited to complete a questionnaire while waiting to see the clinician, or to complete it at home and return it via reply paid envelope. The questionnaire addressed views on key attributes of NIPD, assessed attitudes towards cffDNA testing for CF and asked whether they had had, or would have, an invasive test for CF, if they would have NIPD if available and what their reasons for testing are. The current price of prenatal molecular testing for CF (£370) and NIPD for paternal exclusion (£550) in our Regional Genetics laboratory were used. An estimated price of £750 for the NIPD test currently under development for direct diagnosis was used. Costs of sending in the NIPD sample (£5) and cost of performing the invasive test (£750), which includes chorionic villus sampling, counselling, quantitative fluorescent PCR (QF-PCR) and karyotyping, were obtained from our local fetal medicine unit. NHS reference costs were used to determine the phlebotomy costs, and the cost of feeding back the NIPD results was estimated from Unit Costs of Health and Social Care. 12 The number of women undergoing each test and the total costs of the tests were calculated per 100 pregnancies at risk of CF. As the proportion of carrier parents eligible for NIPD for paternal exclusion is approximately 29.7%, in this pathway, we assumed that the remaining parents were offered invasive testing only. Lastly, we calculated the total number of procedure-related miscarriages for each pathway. Input parameters for the economic analysis are shown in Table 3 . In view of the uncertainty around the number of eligible parents for NIPD for parental exclusion, the uptake of NIPD and IPD and the costs of NIPD, we varied these parameters over a wide range in a sensitivity analysis on the incremental costs of each NIPD pathway compared with the current pathway.
RESULTS
NGS assay development
All eight mutations in the gDNA samples from CF carriers were reliably detected at an allele frequency of 50%. Three normal control samples gave either no or extremely low numbers of mutation reads (zero to 0.09% of wild-type reads) across all amplicons (Table 4) . Sequencing of three controls, using spiked mutant gDNA with three CFTR mutations with an expected mutant allele frequency of 10%, gave percentage mutant allele reads of 10.4%, 8.8% and 4.4% thus demonstrating detection of low level mutant allele targets (Table 4) . In all four maternal plasma cell-free DNA samples, it was possible to accurately determine inheritance of the paternal mutant allele (Table 5) , and the results of NGS panel testing were concordant with mutation status determined by Figure 1 Decision tree depicting the clinical pathways of current invasive testing only, non-invasive prenatal diagnosis (NIPD) for the paternal cystic fibrosis (CF) mutation and NIPD for direct diagnosis traditional testing in all cases. In families 2 and 3, very low (0.02%) or absence of paternal mutation counts in maternal plasma indicated transmission of the wild-type paternal allele. This is consistent with an unaffected fetus at 50% risk of having inherited the maternal mutation, which would be compatible with carrier status. In families 1 and 4, low but significant paternal mutation counts in the maternal plasma (15.9% and 5.9% respectively), which were not seen (family 1) or seen in very low level (0.02%) in the maternal gDNA (family 4), indicated that the fetus had inherited the paternal mutation and was at least a carrier of CF; further testing would be required to determine if the maternal mutation had been inherited.
Applicability of the NGS assay using the ten mutations
An estimated 11.9% of carrier parents in the UK will be heterozygous for a mutation in this NGS panel. As the maternal mutation does not need to be on the panel, we estimate that 29.7% of CF carrier parents in the UK could be offered testing (Table 2) .
Stakeholder views and preferences
One hundred and forty-two potential service users responded to the questionnaire (88.9%). For those affected with CF (n = 92) 45.7% were female, while for carriers of CF (n = 50), the majority were female (72%) and 91.7% had a child affected with CF. The group was well educated, 42.8% having college or other training and 21.7% a degree or equivalent. 9 Of these 142 service users, 131 answered the questions regarding uptake of invasive or NIPD testing. More participants said they would decline (74/131) than would accept (57/131) invasive diagnostic testing for CF. The most common reasons for wanting prenatal diagnosis were 'to prepare for the possible birth of a baby with CF' (n = 33; 62.3%) and to 'help make a decision about whether or not to continue the pregnancy' (n = 17; 32.1%). Most participants (n = 130; 94.9%) said that they would choose NIPD for CF and 90% would be prepared to pay for it, with 49.2% prepared to pay up to £50, 39.0% prepared to pay £100-200 and 10.3% prepared to pay more than £200. One hundred and fourteen participants described potential benefits of NIPD. These fell into five main categories: no miscarriage risk (n = 90), simpler and less stressful test (n = 22), preparation for the birth of an affected child (n = 20), informing decisions around termination of pregnancy (n = 6), earlier testing (n = 6) and more people likely to accept a blood test (n = 9). The 115 responses to questions regarding concerns fell into three main categories: no concerns (n = 101), increase in terminations (n = 13) and increased pressure to terminate (n = 2). No significant differences were seen between responses of carriers and those affected with CF.
Health economics
Total costs were £586 for NIPD for paternal exclusion, £786 for direct diagnosis and £1120 for invasive testing. From the questionnaire responses, we estimated 43% of women at risk of having a baby with CF would have IPD at a total cost of £48 160 per 100 pregnancies at risk, and 28/100 would undergo NIPD for paternal exclusion if available with a total of 36/100 who would undergo invasive testing (six after NIPD, 30 without NIPD). The total cost for this pathway per 100 women was £57 185. We further estimated that 95 women would undergo NIPD for direct diagnosis of CF if available, and none would require invasive testing, costing in total £74 670. NIPD to exclude the paternal CF mutation would therefore increase the costs by £9025, while the incremental costs of NIPD to directly diagnose CF would be £26 510 if compared with the current pathway ( Table 6 ). The rate of miscarriages per 100 pregnancies was low, 0.22 in the current pathway, and implementation of paternal mutation NIPD could lower this to 0.18. No procedure-related miscarriages were expected for NIPD to directly diagnose CF. The sensitivity analysis (Table 7) shows that the incremental costs of each NIPD pathway compared with the current pathway were higher than the base case if more parents were eligible for NIPD (for paternal exclusion pathway only) or if the uptake of NIPD or the costs of NIPD were higher. If the uptake of invasive testing was higher, the incremental costs of both NIPD pathways were lower than the base case value and vice versa. The NIPD pathways were more costly than the current pathway in each scenario.
DISCUSSION
Here, we report the successful development of NIPD for the detection or exclusion of a range of paternal CF mutations. This will reduce the need for invasive diagnostic testing, which will only be required if the paternal mutation is present, as if it is absent, the fetus cannot be affected with Total costs of invasive testing were £370 + £750 = £1120. Total costs of NIPD were £550 + £4 + £5 + £27 = £586 for paternal exclusion and £750 + £4 + £5 + £27 = £786 for direct diagnosis. Costs of pretest genetic counselling and ultrasound for dating and exclusion of multiple pregnancies are not included as it applies equally to all scenarios. NIPD, non-invasive prenatal diagnosis; CF, cystic fibrosis. CF. This approach to NIPD for CF has been approved by the UK Genetic Testing Network, the regulatory body responsible for evaluating new genetic tests and recommending their use within the NHS. 13 Our data clearly indicate the need to optimise PCR conditions for each mutation target and analyse maternal gDNA alongside the plasma sample to assess the level of background in any given sequencing run. In our spiking experiment, one sample showed a significant deviation from the expected level of 10%, and in others, the ratio of wild-type to mutant counts for some heterozygous control samples deviated from the expected level of 50%. It is unclear whether this is due to the quality of individual DNA samples or an intrinsic amplification bias of specific primer pairs. Furthermore, very low 'background' counts were sometimes observed for mutation targets not present in the DNA sample being tested ( Table 2 , cases 2 and 4). It is likely that these are sequencing or PCR-related errors which have occurred during the early stages of amplification that are well documented in the literature.
14 In cases where no paternal mutation is detected in maternal plasma, the presence of cffDNA should be confirmed by analysis of ZFX/ZFY and HLA-B sequences to control against false-negative results occurring because of very low levels of cffDNA in the maternal plasma. 15 To date, the paternal exclusion assays for CF reported in the literature have been developed on a case-by-case basis, usually using PCR-based methodologies, which cannot be applied to multiple different mutations simultaneously in one assay. [6] [7] [8] This approach cannot be readily implemented into a service laboratory where significant throughput of assays testing multiple cases or multiple mutations in a single run are required to optimise turnaround times and minimise costs. We have addressed this by developing an NGS assay that incorporates a panel of mutations, which also allows for expansion of the number of mutations tested for and therefore would be of use to more families. This assay can be used to simultaneously test different families for different mutations as well as testing other samples for different conditions. However, the high frequency of the CFTR mutation p. Phe508del means an estimated 47% of carrier parents will both carry this mutation and will not be eligible to utilise this test. NIPD for recessive disorders where the parental mutations are the same has been demonstrated using relative mutation dosage. 10, 16 These assays are reliant on precise single-molecule counting techniques and accurate assessment of the fetal fraction of cfDNA. The practical limitations of estimating fetal fraction, the number of repeat tests required and the need for a high proportion of cffDNA in the sample have hindered translation into clinical practice. Other approaches to NIPD for direct diagnoses of recessive conditions have been described, including the analysis of single-nucleotide polymorphisms by whole genome sequencing and relative haplotype dosage analysis 17 and targeted NGS. 18 However, costs and time requirements for testing with these methods currently inhibit widespread routine clinical implementation. An approach for offering direct diagnosis when parents carry the same mutation would be to sequence the CFTR mutations alongside several informative single-nucleotide polymorphisms around the CFTR locus; this could facilitate calculation of fetal fraction in the maternal plasma 19 and relative mutation dosage could be used to determine inheritance. 18 This approach is under development in our laboratory, and we have used the predicted costs of this assay in the economic analysis to estimate the cost of direct diagnosis of CF using NIPD. Ideally, implementation of new technologies should be accompanied by stakeholder views and evaluation of costs. Our survey of potential service users showed that interest in NIPD was high, largely due to the improved safety, with over 90% of potential service users reporting they would have NIPD if it was available, compared with 43.5% who would currently consider invasive testing. However, while many stated results would guide decisions about termination, a large proportion would have the test to prepare for the birth of a baby affected with CF. This is compatible with other studies exploring the reproductive choices of couples at risk of CF. 5, [20] [21] [22] [23] [24] Consequently, it is likely that the high potential uptake of NIPD includes many couples who would currently decline invasive testing and who would want testing for information only, rather than to guide decisions around termination of pregnancy. These findings have clear consequences for the cost of prenatal testing for CF in the NHS as the likely increase in uptake means that the cost of a prenatal diagnostic service based on NIPD, whether for the exclusion of the paternal allele or for direct diagnosis, will be significantly higher than the current care pathway based on invasive testing, even if we take into account that hypothetical uptake of genetic tests can differ from actual uptake. [25] [26] [27] When discussing prenatal testing for CF, professionals should be careful to include the fact that early postnatal diagnosis is now available as screening for CF now forms a routine part of neonatal screening in the UK and some other countries, as this may influence decisions of parents committed to continuing the pregnancy. The findings of this cost analysis are quite distinct to a study costing NIPD for fetal sex determination, which found that NIPD was cost neutral for the NHS as the cost of NIPD was offset by the reduction in invasive testing, 28 the key difference being that current rates of invasive testing and termination for serious sex-linked disorders are high by comparison with those for CF. The use of NIPD for CF for information only raises ethical questions around whether, in a state-funded health care system, directing resources to a test that would not change pregnancy management can be justified. 29 In the UK, NIPD for fetal sex determination is used to direct invasive testing in pregnancies at risk of serious sex-linked conditions. However, this test has not been approved for use in women who are carriers of haemophilia, where termination of an affected pregnancy is increasingly rare and fetal gender could be determined by ultrasound at 20 weeks. Accordingly, some clinical services offer NIPD only when it is likely to change clinical management as the additional costs are not balanced by clinical benefits. 30 The definition of clinical benefit is crucial in such policy decisions as there is evidence that there are psychological benefits to early testing and having information to plan and prepare. 31, 32 In addition, decisions may vary from the couple's initial intention once they receive a result.
Table 5
Numbers of reads for the wild-type and mutant sequences with the next-generation sequencing assay for ten common cystic fibrosis Notably, most respondents raised no concerns about NIPD for CF, with a very few worried about the potential for NIPD to increase the number of terminations for CF. These findings are in line with those from qualitative interviews with carriers of other single-gene disorders. 31 
Study limitations
The numbers of clinical cases tested are small, and further cases are needed for ongoing validation. The general applicability of the questionnaire study findings may be limited as the study was conducted in only two regional centres and some groups of potential service users are not well represented, including carrier fathers and carriers without children or whose child with CF has died. Furthermore, responses may vary from those made in real life.
CONCLUSIONS
We have successfully developed an NGS assay to allow NIPD to be used for risk stratification in a significant proportion of CF families. Consideration of stakeholders' views and costeffectiveness alongside test development indicates that introduction of NIPD for CF would be welcomed and uptake is likely to be high. However, as many would use NIPD for CF to inform postnatal management rather than decisions around termination of an affected pregnancy, there are potential economic implications, and further work is required to resolve ethical issues that might arise. These findings may have implications for NIPD for other conditions and highlight the need for prospective consideration of the ethical and economic issues that may arise as more tests are developed.
WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?
• Non-invasive prenatal diagnosis of some single-gene disorders, including CF, is possible by analysis of cell-free fetal DNA in maternal plasma.
WHAT DOES THIS STUDY ADD?
• Use of a next-generation sequencing panel to detect ten common cystic fibrosis (CF) mutations could provide a flexible approach to non-invasive prenatal diagnosis in around 30% of parents who are carriers of CF mutations.
• Potential service users would welcome the introduction of noninvasive prenatal diagnosis for CF.
• As uptake is likely to be high, increased costs for prenatal testing must be considered by policy makers. 
